Related references
Note: Only part of the references are listed.Type 2 diabetes and cardiovascular disease: A metabolic overview of recent clinical trials
Yochai Birnbaum et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial
Kenneth B. Margulies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner
Lukasz Buldak et al.
PHARMACOLOGICAL REPORTS (2016)
Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
Yue Zhou et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart
Li-Hui Zhang et al.
CARDIOVASCULAR DRUGS AND THERAPY (2015)
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
A. J. Scheen et al.
DIABETES & METABOLISM (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Annachiara Uccellatore et al.
DIABETES THERAPY (2015)
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists
Annachiara Uccellatore et al.
DIABETES THERAPY (2015)
The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis
Jessica E. Potts et al.
PLOS ONE (2015)
Exendin-4 Prevents Vascular Smooth Muscle Cell Proliferation and Migration by Angiotensin II via the Inhibition of ERK1/2 and JNK Signaling Pathways
Kosuke Nagayama et al.
PLOS ONE (2015)
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation
K. Pabreja et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2014)
GLP-1 Agonists Inhibit ox-LDL Uptake in Macrophages by Activating Protein Kinase A
Yao Dai et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
Dipeptidyl Peptidase IV Inhibitors and Ischemic Myocardial Injury
Alyssa H. Yoon et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2014)
Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying - preclinical evidence
Ulrich Werner
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2014)
Glucagon-Like Peptide-1 Receptor Agonist Inhibits Asymmetric Dimethylarginine Generation in the Kidney of Streptozotocin-Induced Diabetic Rats by Blocking Advanced Glycation End Product-Induced Protein Arginine Methyltranferase-1 Expression
Ayako Ojima et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a
Craig W. Younce et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2013)
The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE-/- mouse model
Tracey Gaspari et al.
DIABETES & VASCULAR DISEASE RESEARCH (2013)
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
B. Wang et al.
DIABETES OBESITY & METABOLISM (2013)
Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes
Susan Herzlinger et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study
Flip J. P. Bernink et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Exenatide Reduces Final Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction and Short-Duration of Ischemia
Jacob Lonborg et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2012)
Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes
Akira Mima et al.
DIABETES (2012)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A
Yuji Ishibashi et al.
MICROVASCULAR RESEARCH (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms
Yochai Birnbaum et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2012)
GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases
Hari Hendarto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
Tina Vilsboll et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
Mark Fineman et al.
CLINICAL PHARMACOKINETICS (2011)
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
R. Kodera et al.
DIABETOLOGIA (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials
John B. Buse et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level
Yuji Ishibashi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy
Arpita Kalla Vyas et al.
PLOS ONE (2011)
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. E. Ratner et al.
DIABETIC MEDICINE (2010)
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
Hongbin Liu et al.
JOURNAL OF ENDOCRINOLOGY (2009)
GLP-1 Therapy Beyond Glucose Control
Derek J. Hausenloy et al.
CIRCULATION-HEART FAILURE (2008)
Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure-Prone Rat
Indu Poornima et al.
CIRCULATION-HEART FAILURE (2008)
Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice
Cheol Whee Park et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Share Paper
